CBL-514 is under clinical development by Caliway Biopharmaceutics and currently in Phase I for Benign Tumor. According to GlobalData, Phase I drugs for Benign Tumor have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBL-514’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBL-514 is under development for the treatment to reduce local subcutaneous fat (obesity), edematous fibrosclerotic panniculopathy (EFP) cellulite, Dercum's disease and benign tumors such as lipoma. The drug candidate is administered through subcutaneous or parenteral route. The drug candidate consists of plurality of drug-containing micelles formed of a polyoxyethylene castor oil derivative and curcumin substances encapsulated in drug-containing micelles. It acts by targeting DYRK1b.
For a complete picture of CBL-514’s drug-specific PTSR and LoA scores, buy the report here.